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Abstract. In the present study, we have investigated the effect
of the chemical CDK-inhibitor CYC202 on E6 and E7-
transformed keratinocytes, in which the function of the
cellular cell cycle inhibitor p21Cip1 is abrogated by the viral
genes. The cyto-toxicity and the inhibition of the cell growth
were analysed by MTT assay and analysis of DNA synthesis
respectively. The effect on some signalling molecules was
tested by Western blot analysis. CYC202 effectively inhibited
the proliferation of E6 and E7 keratinocytes in a dose-
dependent manner. Treatment with CYC202 strongly
increased the activity of p38 MAP kinase. Furthermore, it
inhibited ERK1/2 at the highest concentration used and had
no effect on the activity of JNK1/2. CYC202 also increased
the phosphorylation of HSP27 and decreased the
phosphorylation and DNA-binding activity of the
transcriptional regulator c-Myc, in correlation with the
corresponding upstream kinases p38 MAPK and ERK1/2. Our
results provide additional data for the anti-proliferative
actions and potency of the chemical CDK-inhibitor CYC202.
Introduction
CYC202 is the R-enantiomer of roscovitine, a specific inhibitor
of the cyclin-dependent kinases, particularly of CDK2 and
CDK7 (1). Most of the studies with CYC202 were directed to
delineate its anti-tumour activities (2-4). Considerable
attention was focused on investigating the anti-cancer
properties of CYC202, however, this agent is also a potent
inhibitor of the cellular growth of normal fibroblasts (5) and
normal epidermal keratinocytes (6). Since tumour cell types
are very sensitive to this compound, CYC202 is undergoing
clinical trials as a cancer treatment (7,8).
Human papillomaviruses (HPV) are small DNA viruses that
are frequently found in cervical carcinomas and in some oral
and laryngeal cancers, especially the high-risk subtypes,
including the most common types HPV16 and HPV18 (9). In
order to amplificate its genome in host cells, HPVs have
developed several strategies to ensure S-phase entry and to
overcome eventual cell cycle arrest. Two of the early viral
genes, E6 and E7 are involved in the maintenance of
proliferation of the host cell. Together, these genes efficiently
immortalize normal human keratinocytes in vitro (10). The
HPV16 E6 and E7 gene products stimulate in the host cells
the cell cycle transition G1-S in the presence of various G1
arrest signals, through interaction with key components of
cellular growth-regulatory pathways (11). E6 interacts with
p53 and leads it to proteasome degradation. The main targets
of E7 are the proteins from the retinoblastoma (Rb) family
(11). E7 interacts with the hypophosphorylated form of Rb
and this interaction results in the release of E2F transcription
factors. Due to the increased transcription, the amount of
cyclin E is elevated (12). The expression of E7 prevents
inhibition of cyclin E-CDK2 by the cellular inhibitor p21Cip1
and the progression of the cell cycle is ensured (13,14).
In the present study, we investigated the effect of the
chemical CDK-inhibitor CYC202 in HPV16 E6- and E7-
transformed keratinocytes, in which the function of the cellular
CDK-inhibitor p21Cip1 is abrogated. The cytotoxicity of
CYC202 and its effect on cellular proliferation were analysed.
We also analysed the effect of CYC202 on some signalling
molecules, which are involved in the control of cell
proliferation, differentiation, and survival. CYC202 effectively
inhibited the proliferation of E6 and E7 keratinocytes in a
dose-dependent manner. Treatment with CYC202 strongly
increased the activity of p38 MAP kinase and the
phosphorylation of its substrate HSP27. In contrast, the
phosphorylation of ERK1/2 MAPK was inhibited by the
highest concentration of CYC202, and this effect
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corresponded with a decrease in the phosphorylation and in
the DNA-binding activity of one of the ERK1/2 substrates,
the transcriptional regulator c-Myc. Our data provide
information relevant to the anti-proliferative effects of this




amino]-9H-purin-2-yl] amino]-1-butanol (CYC202) was
from Cyclacel Ltd. For use in culture medium, CYC202 was
dissolved at 100 mM in DMSO and stored at -20˚C.
The recombinant human epidermal growth factor (EGF)
was purchased from R&D Systems, dissolved according to
the manufacturer's instructions (50 μg/ml stock solution) and
stored at -20˚C.
Cell culture and treatment. The cell cultures were incubated at
37˚C in a 5% CO2 humidified atmosphere. The cell line E6
and E7, derived from normal human keratinocytes through
stable transfection with HPV16 E6 and E7 genes was kindly
provided by Dr Mark Pittelkow (Mayo Clinic, Rochester,
USA). E6 and E7 cells and normal keratinocytes were grown
in Epilife keratinocyte medium (Cascade Biologics),
supplemented with growth factors, hormones and antibiotics.
At ~40% of the culture confluence, the cells were then grown
under autocrine conditions by excluding all growth factors
from the culture medium. 
For treatment with CYC202, different amounts of the stock
solution were added to the autocrine culture medium in order
to obtain 0.1-30 μM CYC202. Control cultures were incubated
with DMSO only.
Determination of cell viability by MTT assay. E6 and E7 cells
were plated in 24-well plates at 5x103 cells/cm2. After
incubation for 24 h with different concentrations of CYC202
in a dose range between 0.1-30 μM, the medium was removed
and substituted with 500 μl/well of MTT solution [0.5 mg/ml
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (Sigma)] and the cells were then incubated in for 2 h
in the dark at 37˚C. MTT solution was then removed, and the
cells were rinsed with phosphate-buffered saline (PBS).
Formazan crystals in each dish were dissolved in 250 μl of
isopropanol during a 30-min incubation on a rocker platform.
Depending on the intensity of the dye concentration, 100 μl
from each sample was diluted with isopropanol and distributed
in a 96-well plate. The absorbance was spectrophoto-
metrically measured at a wavelength of 570 nm. The
measurement was converted into a percentage of cell
viability, using control cultures to determine 100% of cell
viability. Each measurement was performed on quadruplicate
culture wells and the experiment was repeated several times.
The CD50 was determined with curve fitting by GraphPad
software.
Determination of DNA synthesis. E6 and E7 cells were plated
as above in 12-well plates and treated for 24 h with varying
concentrations of CYC202. For the last 2 h of incubation, 1 μCi
[3H]-thymidine (ICN) was added to each well. The
radioactive medium was then removed and the cells were
washed three times with ice-cold PBS and precipitated in 10%
trichloroacetic acid (TCA) for 10 min at 4˚C. The precipitates
were dissolved in 1 ml of 0.3 N NaOH and 0.1% sodium
dodecyl sulphate (SDS). The radioactivity in 500 μl of each
sample was counted in a Beckman liquid scintillation counter
after the addition of Aqualuma. Triplicates of cultures for each
concentration of CYC202 were analyzed and the experiment
was performed several times. The cellular protein content
was determined by the method of Lowry et al (15), and the
rate of DNA synthesis was calculated per μg of protein
content.
Detection of the clonogenic potential of E6 and E7 cell
cultures. E6 and E7 cells were treated with 1-20 μM
CYC202 for 24 h as above. After the treatment, the cells were
trypsinized and then counted. A total number of 2000 cells
were replated in 60-mm Petri dishes and into fresh complete
culture medium. These cultures were incubated for 7 days. At
the end of the culture period, the cells were fixed with 4%
formaldehyde solution in PBS, and then stained with 0.2%
solution of crystal violet for 5 min at room temperature. The
staining solution was discarded and the dishes were washed
three times with distilled water before the photographing of
the cell colonies.
Northern blot analysis. Poly(A) RNA was prepared from
cultures of E6 and E7-transformed and normal keratinocytes
using the method described by Schwab et al (16). The
samples were resolved on 1.2% agarose-formaldehyde gel by
electrophoresis for 3 h at 75 V and then transferred to Zeta-
Probe GT membrane (Bio-Rad). Hybridizations were
performed overnight at 43˚C with randomly primed and [α-
32P] dCTP-labeled DNA probes for HPV16 E6 and E7 early
genes, basal keratin 14, suprabasal keratin 10 and involucrin
as previously described (17). In order to check equivalent
loading and transfer of RNA, the blotted membranes were
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Figure 1. Northern blot analysis of the expression of epidermal
differentiation markers in normal and in E6E7-transformed keratinocytes.
Poly(A) RNA were extracted from normal keratinocytes (NHK) and
transformed keratinocytes (E6E7). Northern blot analysis was performed
with cDNA probes labelled with 32P by random priming, specific for
epidermal differentiation markers: keratin 14, keratin 10, involucrin and for
the house-keeping gene 36B4 (in order to check equivalent loading). The
cDNA for E7 was obtained by RT-PCR from total RNA, extracted from
E6E7 cells.
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further hybridized with a 36B4 cDNA probe (18,19). The
expression of poly(A) RNA was detected and measured with
the Cyclone™ storage phosphor system (Packard BioScience
Co.) after sufficient exposure time of the membrane. 
Western blot analysis. After treatment with CYC202, the cells
were lysed in a sample buffer (0.125 M Tris-HCl, pH 6.8,
20% glycerol, 4% SDS, 0.2 M dithiothreitol (DTT) in
deionised water), detached by scraping and then cleared by
centrifugation at 13,000 rpm at 4˚C for 15 min. Protein
concentration was quantified using Bio-Rad DC protein assay
and equal amounts of protein were used for analysis on 10
or 12% SDS-PAGE. Resolved proteins were transferred
overnight at 4˚C to Hybond-P: PVDF membrane (Amersham
Biosciences). The membrane was then incubated with
blocking buffer (5% non-fat dry milk in 0.1% Tween-20/PBS).
The immunodetection of phosphorylated HSP27, c-Myc and
MAP kinases was performed respectively with rabbit anti-
phospho-HSP27 (Ser82) IgG (Upstate), rabbit anti-phospho
c-Myc (Thr58/Ser62) IgG (Santa Cruz Biotechnology),
mouse monoclonal IgG anti-phospho MAP kinase (ERK1/2),
clone 12D4 (Upstate), mouse monoclonal IgG1 anti-phospho
JNK (Santa Cruz Biotechnology) and rabbit polyclonal anti-
phospho p38[pTpY180/182] (Cell Signalling Technology). After
membrane-stripping, total HSP27, c-Myc, JNK, ERK1/2, p38
were detected respectively with the goat anti-HSP27 (Santa
Cruz Biotechnology), mouse monoclonal IgG1 c-Myc (Santa
Cruz Biotechnology), rabbit SAPK/JNK (Cell Signalling
Technology), rabbit anti-MAP kinase (ERK1/2, Upstate) and
the rabbit anti-p38 MAP kinase (Biosource). Primary
antibodies were then revealed with anti-mouse, anti-goat and
anti-rabbit horseradish peroxidase-conjugated antibodies
(Dako Diagnostics). The detection was performed with
Western blotting luminol reagent (Santa Cruz Biotechnology).
Electrophoretic mobility-shift assay (EMSA). Nuclear extracts
were prepared from E6 and E7 cells treated with CYC202
(0,5, 10, 20 μM). Cells were scraped and lysed in buffer A (10
mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 0.5 mM DTT, 0.2 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 μg/ml protease inhibitor
mixture and 0.5% Nonidet P-40). Nuclei were pelleted by
centrifugation at 13,000 rpm for 10 min at 4˚C. Pellets were
re-suspended in ice-cold hypotonic buffer C (10 mM HEPES
pH 7.9, 420 mM NaCl, 25% glycerol, 0.2 mM EDTA, 0.2 mM
EGTA, 1.5 mM MgCl2, 1 mM DTT, 0.2 mM PMSF and 1
μg/ml protease inhibitor mixture), mixed vigorously by
vortexing and centrifuged at 13,000 rpm for 30 min at 4˚C.
Protein concentration was determined by colorimetric assay
(Bio-Rad).
A double-stranded end-labelled DNA oligonucleotide
(5'-biotin-AGTTGACCACGTGGTCTGGG-3') with a
consensus binding site of c-Myc/Max dimers (Alpha DNA)
was incubated with the nuclear extracts. The binding
reactions were carried out with 15 μg of the respective
nuclear extract protein, 0.5 pmol biotin-labelled DNA, 100 mM
MgCl2, 1% Nonidet P-40, 50% glycerol, 1 μg/μl of poly(dA-
dT) and 10X binding buffer (100 mM Tris pH 7.5, 500 mM
KCl, 10 mM dithiothreitol). The DNA-protein interaction
was allowed to proceed for 15 min at room temperature. The
protein-DNA complexes were resolved on 6% native
polyacrilamide gel in 0.5X TBE and transferred to Biodyne® B
nylon membrane (Pierce). After transfer, the membrane was
immediately cross-linked for 15 min on a UV trans-
illuminator equipped with 312-nm bulbs. A chemi-
luminescent detection was performed with Chemiluminiscent
nucleic acid detection module (Pierce).
Results
Phenotype profile of E6 and E7-transformed keratinocytes.
Firstly, we analysed the phenotype profile of the papilloma-
transformed keratinocytes (E6 and E7) compared to normal
human keratinocytes (NHK), both grown in autocrine
conditions. When epidermal keratinocytes gain confluence
they are committed to differentiation (20). The cells begin to
express the characteristic markers for this process such as
keratin 1, keratin 10, and involucrin. E6 and E7 cells showed
a delayed expression of the differentiation marker involucrin,
which was concomitant with the expression of keratin 1 and
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Figure 2. Comparison between cell viability and [3H]-thymidine incorporation in cultures of E6E7 keratinocytes incubated with CYC202. E6E7 keratinocytes
were treated for 24 h with different concentrations of CYC202 (0.1-20 μM). The cellular viability and the measurement of [3H]-thymidine incorporation into
DNA was performed as it is described in Materials and methods. Data are presented in percent of untreated cells (100%) ± SD averaged from five different
experiments. The concentrations which cause 50% reduction in cell viability (CD50) and which inhibit cell proliferation by 50% (IC50) were calculated by
curve fitting with GraphPad software.
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keratin 10 (Fig. 1). The levels of the two keratins were
elevated and compared to those in normal keratinocytes. To
note, simultaneously with the expression of the differentiation
markers, the level of the viral E7 was weakly decreased. 
Dose-dependent growth inhibition by CYC202. We next
examined the toxicity of the pharmacological agent CYC202
towards HPV16 E6- and E7-transformed keratinocytes. E6
and E7 cells, grown under autocrine conditions were exposed
for 24 h to CYC202, ranging from 0.1-30 μM (the viability at
concentrations higher than 20 μM is not shown) and cellular
viability was determined by an MTT assay (Fig. 2). CYC202
induced a dose-dependent loss in cell viability. The CD50
value determined by curve fi t t ing was ~20 μM
(21.0133±4.66 μM). 
Next, we analysed whether CYC202 exerted an inhibitory
effect on the cellular growth of these transformed cells. The
synthesis of new DNA molecules was measured by the incor-
poration of radio-labelled thymidine ([3H]-thymidine) (Fig. 2).
The level of the [3H]-thymidine incorporation in the newly
synthesised DNA was significantly inhibited by treatment
for 24 h with CYC202 at all tested concentrations. The
concentration at which the proliferation was inhibited at ~50%
(IC50) was determined by curve fitting around 4 μM CYC202
(3.5913±0.575 μM).
The inhibition of cell growth by CYC202 was reversible. In
order to evaluate whether the inhibition of the cellular growth
by CYC202 on E6 and E7-transformed cells could be
reversed after withdrawal of the drug, we performed a clonal
test. E6 and E7 cells were treated for 24 h at specific
concentrations (1, 5, 10 and 20 μM), and then the cells were
trypsinized in order to plate them at a low density in a clonal
assay (21). The concentrations for this experiment were
chosen in the range of concentrations, shown to exert low
toxicity and strong inhibition of the cellular growth (Fig. 2).
Similarly to the previously obtained results with normal
keratinocytes, the CDK inhibitor CYC202 didn't completely
block the cellular growth and soon after withdrawal of the
inhibitor, the viable cells started to divide and form colonies
again. The lowest concentration of CYC202 (1 μM) allowed
similar clonogenicity of E6 and E7 cells to the one observed
in control culture conditions (% compared to the control).
However, the number of colonies was decreased after an
incubation with 5 and 10 μM CYC202 (%) and only rare
colonies were formed by the cells, plated after treatment
with 20 μM CYC202 (Fig. 3). 
Growth arrest by CYC202 was associated with p38 MAPK
activation, but not with ERK1/2 or JNK1/2 activation. To
further investigate the effects of CYC202 on papilloma-
transformed E6 and E7 keratinocytes, we analyzed the
phosphorylation (activation) of the kinases from three MAPK
subfamilies (ERK1/2, p38 MAPK and JNK1/2), which are
associated with the regulation of cellular proliferation,
differentiation, senescence and apoptosis (22,23). 
The phosphorylation of ERK1/2 remained almost
unchanged after treatment with CYC202 up to 10 μM (Fig. 4).
A small decrease was observed at a concentration of the
inhibitor of 20 μM. Mitogenic stimulation with the epidermal
growth factor (EGF) for 15 min increased the level of
phoshorylated ERK1/2. However, EGF did not obviate the
inhibitory effect of the highest concentration of CYC202 on
the activation of ERK1/2, as at these conditions of treatment
inhibition was observed again.
The level of active (phosphorylated) p38 MAPK was dose-
dependently elevated by CYC202 solely and in combination
with EGF (Fig. 4). The most significant increase ~7-fold
compared to control cultures, was observed at 20 μM
CYC202. The effect of the growth factor EGF on the
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Figure 3. Clonal assay of E6E7 keratinocytes after CYC202 treatment. Subconfluent cultures of growing E6E7 keratinocytes were treated for 24 h with
different concentrations of CYC202 (1-20 μM), then the inhibitor was washed and the cultures trypsinized. The cells were counted and 2000 cells from each
treatment were reseeded in 60-mm diameter Petri dishes using fresh complete culture medium containing all growth factors necessary for the cellular
proliferation. After 7 days, the cell colonies were fixed and stained with crystal violet. The bottom of stained dishes was photographed in a scanner.
Keratinocyte cultures treated with DMSO only were used as control.
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phosphorylation of p38 MAPK was comparable with that of
the inhibitor. The combination of EGF with the highest dose
of CYC202 results in analogical phosphorylation of p38
MAPK, similar to the level observed after treatment with this
concentration of CYC202 alone.
The phosphorylation of the kinases from the third MAPK
subfamily JNK1/2 was unchanged by CYC202 alone or in
combination with EGF (Fig. 4). Short stimulation with EGF
did not induce phosphorylation of JNK1/2 kinases in E6 and
E7 keratinocytes.
After activation, each MAPK phosphorylates a spectrum of
substrates, including different transcription factors (22,23).
Therefore we analyzed the activity of two MAPK effectors: the
small heat shock protein 27 (HSP27), which is activated by p38
MAPK; and the transcription factor c-Myc, which is
activated downstream of the ERK1/2 signaling pathway. As
it was expected, the phosphorylation of c-Myc analogous to
that of the ERK1/2 kinases was decreased by the highest
concentration of CYC202 applied solely or when the
treatment was succeeded by short stimulation with EGF (Fig.
5). However, the phosphorylation of HSP27 which is a
substrate of p38 MAPK (24,25) was strongly increased by 20
μM CYC202. Although, the activity of p38 kinase was
elevated also by treatment with lower doses of the inhibitor,
we did not observe any effect on the activation of HSP27 by 5
or 10 μM CYC202, neither alone, nor in combination with
EGF. Stimulation with the growth factor alone had a minimal
effect on the phosphorylation of HSP27, but when it was
preceded by treatment with 20 μM CYC202 the increase was
significant (Fig. 5). 
Because binding to target sequences is essential for c-Myc
function, we have further analyzed whether CYC202
interfered with the DNA binding of the Myc/Max complexes
by EMSA. The binding of the protein to the target DNA
sequence results in a single retarded band at electrophoresis.
Inhibition with CYC202 up to 10 μM had no effect on the
c-Myc DNA-binding activity, however treatment with 20 μM
CYC202 decreased the binding of nuclear extracts to the
synthetic oligonucleotide containing Myc/Max consensus
sequence (Fig. 6). 
Discussion
Many epithelial malignancies, including cervical cancer are
often associated with small DNA viruses from the papilloma
family. The replication of the viral genome is dependent on the
host cell, and HPVs have developed several strategies to
ensure cell cycle progression. Mainly two of the viral genes,
E6 and E7, are implicated in cell transformation leading to
continuous proliferation and immortalization of normal cells
(10). The products of the E6 and E7 genes interact with
tumour suppressors and this interaction abrogates the function
of these regulatory molecules. One of the cell proteins, whose
activities are interrupted by the expression of the viral
oncogenes, is the cyclin-dependent kinase inhibitor p21Cip1.
Jones et al show in their study that the abrogation of p21Cip1-
mediated inhibition of CDK2 activity is important for the
uncoupling of the processes of keratinocyte proliferation and
differentiation, leading to indefinite cellular proliferation
(13). In this case, CYC202 might be a useful pharmacological
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Figure 5. Analysis of the phosphorylation of c-Myc and HSP27 after
incubation of E6E7 keratinocytes with CYC202. E6E7 keratinocytes were
incubated for 24 h with CYC202 in concentrations of 0, 5, 10, or 20 μM and
(or without) recombinant EGF (10 ng/ml). After lysis, Western blotting
transferred equal amounts of proteins which were used for detection of
phosphorylated and total c-Myc and HSP27 using specific antibodies.Figure 4. Analysis of the phosphorylation of ERK1/2, JNK1/2 and p38
MAPK kinase in E6E7 keratinocytes incubated with CYC202. E6E7 cells
incubated with 0, 5, 10 or 20 μM CYC202 for 24 h and (or without)
recombinant EGF (10 ng/ml) were lysed and equal amounts of proteins were
used for Western blot analysis of the basal and phosphorylated ERK1/2, p38
MAPK and JNK1/2. 
Figure 6. Electrophoretic mobility-shift assay. E6E7 keratinocytes were
incubated for 24 h with CYC202 (0,5,10 or 20 μM). Nuclear extracts were
prepared and EMSA analysis of Myc/Max binding activity was performed,
as described in ‘Materials and methods’. Lane 1: protein extract from
control cultures, incubated with DMSO only; Lane 2: protein extract from
cultures incubated with 5 μM CYC202; Lane 3: protein extract from
cultures incubated with 10 μM CYC202; Lane 4: protein extract from
cultures incubated with 20 μM CYC202; Lane 5: c-Myc oligonucleotide
without protein extract.
999-1005  10/9/07  10:29  Page 1003
inhibitor of the cell growth of papilloma-infected cells and
perhaps could be applied for therapy of papilloma-induced
malignancies. Therefore, in this study we investigated the
action of the CDK-inhibitor CYC202 on HPV16 E6- and E7-
transformed keratinocytes.
To be useful for clinical application, similar to every anti-
cancer agent, CYC202 must be several times more potent
towards transformed cells, rather than inhibiting the growth
of the normal human cells. In light of its nature, CYC202 is a
more potent inhibitor of the cellular growth of highly
proliferating cells (2). Despite the transformation, in our culture
conditions, E6 and E7 cells proliferated almost in the same
manner as autocrine cultures of normal keratinocytes. Even
more, the E6 and E7 cells were still capable of differentiating.
Accordingly, the gain in cell confluence was associated with
the expression of keratinocyte differentiation markers keratin
1, keratin 10 and involucrin, but compared to normal
keratinocytes this expression was shortly delayed. This
observation remains in accordance with the reports of other
investigators suggesting that HPV16 E6- and E7-expressing
keratinocytes have delayed differentiation, partially uncoupled
from the cellular proliferation (9,13). Nguyen et al have
reported that although HPV16 E7 can delay differentiation-
induced growth arrest, HPV16 E7-expressing cells are still
capable of differentiating and the viral gene does not
interfere with differentiation-specific gene expression (11). 
The first step for the analysis of the effects of CYC202 on
culture of E6 and E7-transformed keratinocytes was to
determine the effective dose of the agent at inhibiting cell
growth without affecting the cell viability. Significant growth
inhibition was observed at weakly toxic concentrations. The
distinction between the concentration of CYC202 with a
strong cytotoxic effect, e.g. CD50, and the concentration that
effectively inhibits  the cell proliferation, e.g. IC50, permits the
utilization of CYC202 for E6 and E7 growth inhibition. The
effective concentration of CYC202 for growth inhibition of
E6 and E7-transformed keratinocytes was almost 2-fold
lower than that exerted towards proliferating normal
keratinocytes (6). Probably, the analogical proliferative state
of E6 and E7- transformed and normal keratinocytes is the
reason for almost the same susceptibility to growth inhibition
by CYC202.
In addition, with the inhibition of the cell cycle on the level
of CDK kinases, CYC202 interferes with several signal
transduction pathways and this has consequences for the cell's
choice between proliferation, differentiation or death (3,26,27).
The MAPK signaling pathways are implicated in the regulation
of these processes and have been shown to respond to a broad
range of external stresses and drugs, including CYC202
(3,22). In general, the ERK cascade is believed to mediate both
cell proliferation and survival, whereas p38 MAPK and JNK
are activated in response to cellular stress (28,29).
Complementary to the inhibition of DNA synthesis,
CYC202 abolished the proliferative effects of the transforming
viral genes also at the level of the signal-transduction
pathways. In accordance, the activities of the MAP kinases
associated with the cellular growth, ERK1/2, were inhibited.
The transcriptional regulator c-Myc is necessary for
keratinocyte proliferation and is one of the downstream
effectors of the ERK1/2 signaling pathway (23). In addition, it
was reported that E6 of HPV16 associates with Myc and this
complex functions to transactivate the gene of human
telomerase reverse transcriptase and hence constitutes a major
immortalizing activity of E6 (30). Therefore, the phos-
phorylation of c-Myc on Thr58/Ser-62, targeted by active
ERK1/2 MAP kinases, was inhibited by treatment with 20 μM
CYC202, in correlation with the inhibition of the cellular
growth and the phosphorylation of ERK1/2 kinases. Even
more, the highest concentration of CYC202 decreased c-Myc
DNA-binding activity, which is essential for its function as a
transcriptional regulator, and this result confirmed the negative
effect of CYC202 on the activity of some signaling molecules
implicated in the regulation of the cellular proliferation.
Recent studies reported the reverse correlation between
the activity of the other subfamily of MAP kinases, p38
MAPK, and that of ERK1/2, as a result of complex formation
between these kinases (31,32). This reciprocal activity of the
two subfamilies of MAP kinases, was observed previously
when we studied the effects of CYC202 on normal human
keratinocytes (6). Analogically, in E6 and E7 cells the
inhibition of ERK1/2 by the highest concentration used (20
μM) coincided with a strong increase in the phosphorylation
of the stress kinase p38 MAPK. The activity of this kinase
was proved further by the phosphorylation of one of its
substrates, the small heat shock protein hsp27 (24,25). In a
previous study, we attributed the induction of p38 MAPK and
the subsequent phosphorylation of hsp27 to a stress response
towards the inhibitor CYC202 (6). However, here we showed
that the activity of the other subfamily MAP kinases
associated with stress reactions, JNK1/2, was not affected by
treatment with CYC202. In light of the evidence, that MAPK
can influence cell cycle progression and the p38 MAPK
pathway is a primary pathway activated by agents that inhibit
the progression of the cell cycle (29,33), the activation of this
kinase by CYC202 possibly is a result of cell cycle arrest
induced by the CDK-inhibitor. 
In conclusion, this study demonstrated that HPV16 E6
and E7-transformed keratinocytes are sensitive to the anti-
proliferative actions of the CDK-inhibitor CYC202. The
inhibition of the cellular growth was associated with changes
in the activity of some molecules, participating in the regulation
of this process. CYC202 inhibits the activity of ERK1/2 MAP
kinases, but strongly activates the stress kinase p38 MAPK.
These data suggest an important interplay between p38 MAPK
and cell cycle control and also provide additional insights for
the potency of the CDK-inhibitor CYC202.
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